
Syphilis Immunoassay Diagnostics Market Report and Forecast 2025-2034
Description
The syphilis immunoassay diagnostics market size in the 7 major markets was valued at USD 411.40 Million in 2024, driven by the incidence of syphilis cases in the major markets. The market is expected to grow at a CAGR of 3.00% during the forecast period of 2025-2034, with the values likely to rise from USD 552.89 Million by 2034.
Syphilis Immunoassay Diagnostics: Introduction
Syphilis immunoassay is a type of diagnostic method used to check if a patient is affected with syphilis. Syphilis is a bacterial infection. It is a sexually transmitted disease which spreads through oral, vaginal, or anal sexual contact. It may even pass down from a pregnant woman to the fetus.
The diagnosis is done via measuring certain antibody levels in the blood. It can be done through a blood test called rapid plasma regain (RPR) or through a blood or spinal fluid test called venereal disease research laboratory (VDRL) test.
Syphilis Immunoassay Diagnostics Market Analysis
Syphilis is the oldest known sexually transmitted disease, affecting a substantial portion of adults, falling in the age category of 15 to 49 years. Over the years, the incidence of Syphilis cases has increased by 32%. Therefore, there has been emphasis on diagnosing, preventing, and treating the disease. This has resulted in an increased syphilis immunoassay diagnostics market demand.
Syphilis is caused by the gram-negative bacterium Treponema pallidum. Currently, most of the syphilis detection is investigated through T. pallidum IgG chemiluminescence immunoassay (CLIA), which is a qualitative assay performed to detect the antibodies against the bacteria in the body. Owing to the array of CLIA applications, Fapon Biotech has developed around 80 different CLIA tests. The CLIA Analyzer Shine i8000/9000 produces high outputs for rapid and reliable clinical diagnosis. It does not require any extensive maintenance either. Therefore, the syphilis immunoassay diagnostics market value is certain to rise with such technologies.
As syphilis can also be transmitted to newborns via mother, there has been focus on preventing developing methods to detect congenital syphilis in children. The researchers from UTHealth Houston are developing a medical diagnostic test for the detection of congenital syphilis to facilitate early treatment. This method can turn out to be promising in the future as 60% of untreated syphilis infected infants suffer from neurodevelopmental issues.
Syphilis Immunoassay Diagnostics Market Segmentation
Syphilis Immunoassay Diagnostics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The United States is expected to lead the syphilis immunoassay diagnostics market share. As sexually transmitted diseases continue to rise in the region, the government has been setting several awareness campaigns to spread awareness and prevent the illness. ‘Girl, Get Tested’ is a notable public awareness campaign promoting syphilis screening in cisgender women. In addition, the United States also has prominent healthcare companies which continue to bring newer technologies.
The Asia Pacific region, especially Japan, is estimated to observe fastest growth, owing to the increasing prevalence of developing a well-equipped infrastructure for research and development. The syphilis immunoassay diagnostics market growth can be accredited to several awareness initiatives. For example, in March 2023, the Australian government initiated ‘Let your partners know’ syphilis awareness campaign envisioned to encourage contact tracing for people who have tested positive to syphilis. The aim is to ultimately increase syphilis testing and treatment.
Syphilis Immunoassay Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Syphilis Immunoassay Diagnostics: Introduction
Syphilis immunoassay is a type of diagnostic method used to check if a patient is affected with syphilis. Syphilis is a bacterial infection. It is a sexually transmitted disease which spreads through oral, vaginal, or anal sexual contact. It may even pass down from a pregnant woman to the fetus.
The diagnosis is done via measuring certain antibody levels in the blood. It can be done through a blood test called rapid plasma regain (RPR) or through a blood or spinal fluid test called venereal disease research laboratory (VDRL) test.
Syphilis Immunoassay Diagnostics Market Analysis
Syphilis is the oldest known sexually transmitted disease, affecting a substantial portion of adults, falling in the age category of 15 to 49 years. Over the years, the incidence of Syphilis cases has increased by 32%. Therefore, there has been emphasis on diagnosing, preventing, and treating the disease. This has resulted in an increased syphilis immunoassay diagnostics market demand.
Syphilis is caused by the gram-negative bacterium Treponema pallidum. Currently, most of the syphilis detection is investigated through T. pallidum IgG chemiluminescence immunoassay (CLIA), which is a qualitative assay performed to detect the antibodies against the bacteria in the body. Owing to the array of CLIA applications, Fapon Biotech has developed around 80 different CLIA tests. The CLIA Analyzer Shine i8000/9000 produces high outputs for rapid and reliable clinical diagnosis. It does not require any extensive maintenance either. Therefore, the syphilis immunoassay diagnostics market value is certain to rise with such technologies.
As syphilis can also be transmitted to newborns via mother, there has been focus on preventing developing methods to detect congenital syphilis in children. The researchers from UTHealth Houston are developing a medical diagnostic test for the detection of congenital syphilis to facilitate early treatment. This method can turn out to be promising in the future as 60% of untreated syphilis infected infants suffer from neurodevelopmental issues.
Syphilis Immunoassay Diagnostics Market Segmentation
Syphilis Immunoassay Diagnostics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Analyzers
- Kits
- Reagents
- CLIA
- ELISA
- Others
- Hospitals
- Diagnostic Labs
- Blood Banks
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
The United States is expected to lead the syphilis immunoassay diagnostics market share. As sexually transmitted diseases continue to rise in the region, the government has been setting several awareness campaigns to spread awareness and prevent the illness. ‘Girl, Get Tested’ is a notable public awareness campaign promoting syphilis screening in cisgender women. In addition, the United States also has prominent healthcare companies which continue to bring newer technologies.
The Asia Pacific region, especially Japan, is estimated to observe fastest growth, owing to the increasing prevalence of developing a well-equipped infrastructure for research and development. The syphilis immunoassay diagnostics market growth can be accredited to several awareness initiatives. For example, in March 2023, the Australian government initiated ‘Let your partners know’ syphilis awareness campaign envisioned to encourage contact tracing for people who have tested positive to syphilis. The aim is to ultimately increase syphilis testing and treatment.
Syphilis Immunoassay Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- BioRad Laboratories Inc
- Danaher Corporation
- BECTON DICKINSON & COMPANY
- F. Hoffmann-La Roche AG
- Siemens Healthineers AG
- Diasorin S.P.A
- Abbott
- Fujirebio
- BioMerieux SA
- Shenzhen New Industries Biomedical Engineering Co. Ltd
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Syphilis Disease Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Syphilis Disease Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.3.2 France Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Syphilis Disease Epidemiology Forecast (2018-2034)
- 5.4 Japan Syphilis Disease Epidemiology Forecast (2018-2034)
- 6 Syphilis Immunoassay Diagnostic Market Overview – 7MM
- 6.1 Syphilis Immunoassay Diagnostic Market Historical Value (2018-2024)
- 6.2 Syphilis Immunoassay Diagnostic Market Forecast Value (2025-2034)
- 7 Syphilis Immunoassay Diagnostic Market Landscape – 7MM
- 7.1 Syphilis Immunoassay Diagnostic: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Syphilis Immunoassay Diagnostic Product Landscape
- 7.2.1 Analysis by Product Type
- 7.2.2 Analysis by Technology
- 8 Syphilis Immunoassay Diagnostic Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Syphilis Immunoassay Diagnostic Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Syphilis Immunoassay Diagnostic Market Segmentation – 7MM
- 11.1 Syphilis Immunoassay Diagnostic Market by Product Type
- 11.1.1 Market Overview
- 11.1.2 Analyzers
- 11.1.3 Kits
- 11.1.4 Reagents
- 11.2 Syphilis Immunoassay Diagnostic Market by Technology
- 11.2.1 Market Overview
- 11.2.2 CLIA
- 11.2.3 ELISA
- 11.2.4 Others
- 11.3 Syphilis Immunoassay Diagnostic Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Diagnostic Labs
- 11.3.4 Blood Banks
- 11.3.5 Others
- 11.4 Syphilis Immunoassay Diagnostic Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Syphilis Immunoassay Diagnostic Market
- 12.1 Syphilis Immunoassay Diagnostic Market Historical Value (2018-2024)
- 12.2 Syphilis Immunoassay Diagnostic Market Forecast Value (2025-2034)
- 12.3 Syphilis Immunoassay Diagnostic Market by Product Type
- 12.4 Syphilis Immunoassay Diagnostic Market by Technology
- 13 EU-4 and United Kingdom Syphilis Immunoassay Diagnostic Market
- 13.1 Syphilis Immunoassay Diagnostic Market Historical Value (2018-2024)
- 13.2 Syphilis Immunoassay Diagnostic Market Forecast Value (2025-2034)
- 13.3 Germany Syphilis Immunoassay Diagnostic Market Overview
- 13.3.1 Syphilis Immunoassay Diagnostic Market by Product Type
- 13.3.2 Syphilis Immunoassay Diagnostic Market by Technology
- 13.4 France Syphilis Immunoassay Diagnostic Market Overview
- 13.4.1 Syphilis Immunoassay Diagnostic Market by Product Type
- 13.4.2 Syphilis Immunoassay Diagnostic Market by Technology
- 13.5 Italy Syphilis Immunoassay Diagnostic Market Overview
- 13.5.1 Syphilis Immunoassay Diagnostic Market by Product Type
- 13.5.2 Syphilis Immunoassay Diagnostic Market by Technology
- 13.6 Spain Syphilis Immunoassay Diagnostic Market Overview
- 13.6.1 Syphilis Immunoassay Diagnostic Market by Product Type
- 13.6.2 Syphilis Immunoassay Diagnostic Market by Technology
- 13.7 United Kingdom Syphilis Immunoassay Diagnostic Market Overview
- 13.7.1 Syphilis Immunoassay Diagnostic Market by Product Type
- 13.7.2 Syphilis Immunoassay Diagnostic Market by Technology
- 14 Japan Syphilis Immunoassay Diagnostic Market
- 14.1 Syphilis Immunoassay Diagnostic Market Historical Value (2018-2024)
- 14.2 Syphilis Immunoassay Diagnostic Market Forecast Value (2025-2034)
- 14.3 Syphilis Immunoassay Diagnostic Market by Product Type
- 14.4 Syphilis Immunoassay Diagnostic Market by Technology
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding and Investment Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnerships and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 BioRad Laboratories Inc
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisitions
- 20.1.5 Certifications
- 20.2 Danaher Corporation
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisitions
- 20.2.5 Certifications
- 20.3 BECTON DICKINSON & COMPANY
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisitions
- 20.3.5 Certifications
- 20.4 F. Hoffmann-La Roche AG
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisitions
- 20.4.5 Certifications
- 20.5 Siemens Healthineers AG
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisitions
- 20.5.5 Certifications
- 20.6 Diasorin S.P.A
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisitions
- 20.6.5 Certifications
- 20.7 Abbott
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisitions
- 20.7.5 Certifications
- 20.8 Fujirebio
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisitions
- 20.8.5 Certifications
- 20.9 BioMerieux SA
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisitions
- 20.9.5 Certifications
- 20.10 Shenzhen New Industries Biomedical Engineering Co. Ltd
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisitions
- 20.10.5 Certifications
- 21 Syphilis Immunoassay Diagnostic Market- Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.